TBPH: Two Downgrades in a Day Signal Street Shift

The short interest picture is less charged than that analyst headline suggests. Bears hold 9.2% of the free float short — meaningful for a pharma name, but that position has been shrinking. Short interest fell almost 7% over the past week and is down around 6.6% over the past month, with the short count easing from above 5 million shares in mid-June to roughly 4.7 million now. The borrow market remains very loose — availability is running at over 500% of short interest, meaning shares to borrow far outnumber those already borrowed, and cost to borrow is only 0.55%, even after rising 35% on the week from an already low base. There is no mechanical squeeze tension here. The ORTEX short score has drifted down from 72.4 on June 22 to 66.4 this week, reflecting the easing in positioned short interest even as the fundamental picture clouds over.

Options traders have actually turned less defensive than they were. The put/call ratio has dropped sharply from above 12 in late May — an extreme level dominated by put-heavy positioning — to 4.45 now, sitting 1.5 standard deviations below its 20-day average of 6.4. That is a material shift toward call activity relative to the recent norm. It could reflect put holders rolling off protection bought around the March trial failure, or renewed speculative interest in call upside, possibly tied to the unresolved strategic review. Either way, options positioning has moved away from pure defensiveness over the past six weeks, even as the sell-side has grown more cautious.

Insider and institutional activity adds a wrinkle worth watching. Madison Avenue Partners — the largest holder at 17.8% of shares — sold roughly $5.8 million worth of stock across three days between June 29 and July 1. That is a concentrated block of selling from the top holder at the precise moment the two analyst downgrades landed. On the institutional side, BlackRock, State Street, and Geode all added shares, and Newtyn Management built a meaningful position during Q1. The net insider flow over 90 days is technically positive by share count, but that is distorted by earlier activity. The Madison Avenue selling is the freshest signal, and it is directional.

Earnings are due August 3. The stock's recent history around results has been muted — moves of less than 1% on the day in two of the last four prints, with the March 19 announcement being the outlier at plus 3.6% on the day and nearly 10% over five days. With the strategic review still open and two downgrades just filed, whether any corporate announcement accompanies the Q2 print is the question that will dominate positioning between now and then.